Table 1. Summary of baseline characteristics.
| Variable | Study cohort (n = 43) |
|---|---|
| Age, years | 72.0 (68.0–76.5) |
| Female sex | 6 (14.0%) |
| Hypertension | 36 (83.7%) |
| Diabetes mellitus | 17 (39.5%) |
| Hyperlipidemia | 23 (53.5%) |
| Coronary artery disease | 2 (4.7%) |
| Current smoking | 12 (27.9%) |
| Statin | 34 (79.1%) |
| Proton pump inhibitor | 36 (83.7%) |
| Cilostazol | 2 (4.7%) |
| Oral anti-coagulant | 3 (7.0%) |
| Duration of clopidogrel use before treatment, days | 27 (18.5–85.5) |
| Hemoglobin, g/dL | 13.9 (12.6–14.5) |
| Platelets, ×103/mL | 21.2 (18.6–25.6) |
| Serum albumin, mg/dL | 4.2 (3.9–4.4) |
| Symptomatic lesion | 21 (48.8%) |
| NASCET, %* | 69.3 (62.5–79.9) |
| General anesthesia | 42 (97.7%) |
| 9-Fr guiding catheter | 36 (83.7%) |
| Closed stent | 35 (81.4%) |
| Flow reversal | 35 (81.4%) |
Continuous variables are presented as median (interquartile range).
* The degree of carotid artery stenosis measured using the NASCET method.
NASCET: North American Symptomatic Carotid Endarterectomy Trial